Unicycive

Chronic kidney disease (CKD) can progress with few or no symptoms early on – and it can affect more than just the kidneys. In advanced CKD, the kidneys may struggle to remove extra phosphorus, leading to hyperphosphatemia (high phosphorus).

Learn more about CKD and the prevalence of hyperphosphatemia: https://unicycive.com/our-focus/

Our CEO Shalabh Gupta, MD and Patient Advocate Leader Valen Keefer have something to share with the kidney disease community soon. Stay tuned ... 👀 for real conversations about living with kidney disease and our commitment to helping address common challenges.

Our work in kidney disease is grounded in a simple idea: Building trust with the patient community is critical to understanding real challenges and finding innovative strategies. Our CEO Shalabh Gupta shares more about our approach. Learn more: https://unicycive.com/our-approach/

Collaborating with such a passionate and talented group of individuals makes our mission even more rewarding. Together, our Unicycive team is committed to advancing healthcare and delivering therapies that truly make a difference. Hear more from Anne Marie Schauman and Mitchell Freidberg.

Current treatments to manage pose a range of challenges that can impact patients’ quality of life.

Pablo Pergola discusses difficulties faced when treating this condition and how we are committed to addressing it.

November is National Family Caregivers Month. Caregivers play invaluable roles in supporting loved ones living with chronic kidney disease. Join us in recognizing their unwavering commitment and expressing our gratitude for their tireless work.

Yesterday at we presented results for our investigational phosphate binder for patients with chronic kidney disease (CKD). The findings showed significant reductions in both pill volume and pill burden for CKD patients with hyperphosphatemia. Learn more about our key findings and what it could mean for patients who struggle to improve phosphate control: https://unicycive.com/oxylanthanum-carbonate-achieves-serum-phosphate-control-with-significantly-lower-pill-burden-in-dialysis-patients-with-hyperphosphatemia/